An Introduction to Haematology
The field of haematology is far-reaching, encompassing many conditions of the blood and blood-forming organs, including anaemia, bleeding and coagulation disorders, sickle cell disease, congenital immunodeficiency diseases, transfusion medicine and haematopoietic stem cell transplantation. There continue to be many obstacles to gene therapy but ultimately this approach holds promise in inherited blood disorders. In addition, novel anticoagulant therapies, multiplexed sensing platforms and the application of artificial intelligence in diagnosis and monitoring are proving valuable in clotting disorders.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.
ZUMA-23 study of axicabtagene ciloleucel as first-line therapy in large B-cell lymphoma: Jason Westin, EHA 2023
ZUMA-23 (NCT05605899) is an on-going phase 3 study investigating axicabtagene ciloleucel (axi-cel) CAR T cell therapy as a first-line therapy in patients with high-risk large B-cell lymphoma. touchONCOLOGY caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss what previous clinical trials have taught us about […]
Axicabtagene ciloleucel for the treatment of large B-cell lymphoma: Jason Westin, EHA 2023
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved to treat patients with relapsed/refractory large B-cell lymphoma. We caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss the current treatment paradigm for large B-cell lymphoma, the limitations of current […]
Key considerations for treatment selection and sequencing in patients with RRMM: Lessons from real-life clinical practice
Watch three specialists discuss patient cases and share their insights on optimization of treatment selection and sequencing in relapsed/refractory multiple myeloma (RRMM).
- Interpret factors that must be balanced when choosing therapy for patients with RRMM who have relapsed following 1–3 prior lines of therapy
- Evaluate alternative treatment strategies for patients with RRMM following >3 prior lines of therapy
- Identify optimal sequencing strategies for patients with RRMM in both early- and later-line settings
Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management
Experts answer questions with in-depth advice on the current clinical landscape and how new guidelines might impact regional clinical practice. Useful tips below will show how to navigate the activity.
- Describe the clinical presentation and the diagnostic process for MDS and AML
- Demonstrate how the pathophysiology of MDS and AML determines disease classification
- Outline the updated risk stratification guidelines for MDS and AML and the implications for patient management
Navigating pyruvate kinase deficiency today: How can the disease burden and unmet treatment needs be addressed?
Three experts discuss the burden and clinical presentation of pyruvate kinase deficiency, as well as current and emerging therapeutic strategies.
- Recognize the signs and symptoms of PK deficiency and the burden of disease in affected patients
- Evaluate established therapeutic strategies for PK deficiency and identify remaining unmet treatment needs
- Describe novel and emerging therapeutic strategies for PK deficiency and how they may address current unmet needs
What’s on the horizon for higher-risk MDS? An update on emerging novel agents
Dr David Sallman reviews advances in HR-MDS management, including the mode of action and latest clinical data for emerging treatments.
- Recall the mechanisms of action for key emerging treatments for patients with HR-MDS
- Describe the latest efficacy data for key emerging treatments for patients with HR-MDS
- Discuss the safety profile of key emerging treatments for patients with HR-MDS
Bernd Jilma, ASH 2022: Pegcetacoplan in patients with cold agglutinin disease, the CASCADE phase III trial
The CASCADE trial aims to assess the efficacy and safety of pegcetacoplan in patients with cold agglutinin disease (CAD). In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the CASCADE trial and when results should be expected. The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled […]
Bernd Jilma, ASH 2022: The pathophysiology and unmet treatment needs in cold agglutinin disease
Cold agglutinin disease (CAD) is a rare, autoimmune, clonal B cell disorder. In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the pathophysiology of CAD and the unmet treatment needs in this disease. The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study […]
Srdan Verstovsek, ASH 2022: Momelotinib long-term safety in myelofibrosis disease – Analysis of SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials
Momelotinib, an oral JAK1/JAK2/ACVR1 inhibitor, was evaluated in 3 randomised controlled trials – SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM, in patients with high- and intermediate-risk myelofibrosis. In this touchONCOLOGY interview, we speak with Prof. Srdan Verstovsek (MD Anderson Cancer Center, Houston, TX, USA) to discuss the limitations of JAK inhibitor therapy in myelofibrosis, and the integrated analysis of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!